Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/Phase 2 study of ACTinium in metastatic castration-resistant prostate cancer following prior …
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC [Phase 2]
ClinicalTrials.gov update for a Phase 2 study evaluating efficacy, safety, pharmacokinetics, and dosimetry of Lu-177 PSMA-617 in Chinese adu…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs [NA]
A completed clinical trial update investigating microRNA expression as predictive factors for treatment resistance in metastatic castration-…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 study evaluating enfortumab vedotin as monotherapy in metastatic castration-resistant prostate cancer; trial is currently active and…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors [Phase 2]
A Phase 2 study evaluating vobramitamab duocarmazine in metastatic castration-resistant prostate cancer and other solid tumors was terminate…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer [Phase 2]
This is a Phase 2 clinical trial evaluating the combination of pertuzumab, trastuzumab, hyaluronidase-zzxf, and enzalutamide for metastatic …
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 2]
This entry covers a Phase 2 clinical trial evaluating Bipolar Androgen Therapy (BAT) in combination with Radium-223 for metastatic castratio…
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer [Phase 2]
A Phase 2 trial of Erdafitinib in castration-resistant prostate cancer was terminated; the document provides the status update without repor…
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [EARLY_Phase 1]
This early-phase Phase 1 trial evaluates the safety and preliminary efficacy of combining LC-K76 with an anti-PD-1 therapy in patients with …
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) [Phase 1, Phase 2]
This is a clinical trial update for SECuRE, investigating 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for identification and treatment of PSMA-exp…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy [Phase 3]
A Phase 3 clinical trial is evaluating whether adding rucaparib to enzalutamide improves outcomes for men with metastatic castration-resista…
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer [Phase 1]
Phase 1 safety and dose-finding study of PRL-02 Depot in men with advanced prostate cancer is currently recruiting, indicating early clinica…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer [Phase 3]
A Phase 3 study evaluating HRS-4357 versus novel androgen receptor pathway inhibitors for PSMA-positive metastatic castration-resistant pros…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 1]
A Phase 1 study evaluating valemetostat (DS-3201b) in combination with darolutamide for metastatic castration-resistant prostate cancer is c…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer [Phase 1]
A Phase 1 clinical trial evaluating BMS-986460 in participants with metastatic castration-resistant prostate cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
Clinical trial update describing gene expression analyses in patients with metastatic prostate cancer treated with a CYP-17 inhibitor.
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer [Phase 2]
This clinical trial update describes a Phase 2 study evaluating the combination of apalutamide with carotuximab for metastatic castration-re…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [EARLY_Phase 1]
This Phase 1 trial evaluates the safety, tolerability and preliminary efficacy of the PSMA-targeted radioligand 161Tb-LNC1011 in patients wi…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate Cancer
Development and prospective validation of a pathology-based AI model to predict the time to castration resistance in prostate cancer.
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan [Phase 4]
Phase 4 clinical trial pilot evaluating 18F-DCFPyL-PSMA PET imaging in men with metastatic castration-resistant prostate cancer who are rece…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer-sponsored real-world evidence study on metastatic prostate cancer (metastatic castration-sensitive and metastatic castration-resistan…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Study With [225Ac]Ac-FL-020 in mCRPC Participants [Phase 1]
A Phase 1 clinical trial update for [225Ac]Ac-FL-020 in metastatic castration-resistant prostate cancer. The study (NCT06492122) is currentl…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer [Phase 3]
A Phase 3 clinical trial comparing BMS-986365 to investigator's choice therapy in metastatic castration-resistant prostate cancer, currently…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial evaluating the efficacy of combining hypoxia-targeting therapy with an ARSI after first-line ARSI in castration-res…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial evaluating the combination of vorinostat and Lutetium-177 PSMA-617 for PSMA-low metastatic castration-resistant pro…